Trial development and scientific contribution by the investigators of The Children's Hospital of New York-Presbyterian at Columbia University, Pediatric Cancer Foundation Developmental Therapeutics Program (PCFDTP) led by Dr. Julia Glade Bender. See 2010 renewal description.
Principal Investigator Name:
Julia Glade Bender, MD
Project Title:
A New York Based Pediatric Oncology Developmental Therapeutics Program
Despite advances in the treatment of cancer, the outcome for some of the most common childhood cancers remains extremely poor. Our pediatric oncology program at Children’s Hospital and Regional Medical Center is committed to investigate how to best administer currently available chemotherapy agents and how to develop new therapies for these childhood cancers. A successful Phase I/II clinical trial program is essential to our mission of advancing treatment of pediatric cancer and providing options to families and patients fighting cancer.
Neuroblastoma is the most frequently diagnosed cancer in infancy, comprises more than 7% of cancers in patients younger than 15 years of age, and is responsible for 15% of all childhood cancer deaths. There remains a need for novel treatment strategies to eliminate residual disease resistant to current therapies. We will study if natural killer (NK) cells, an important cell in our immune system, and the immune genes responsible for their behavior play a role in the control and eradication of neuroblastoma.
Principal Investigator Name:
Katharine Hsu
Project Title:
The role of immunogenetics in natural killer cell targeting of neuroblastoma
Hux is 7 years old and a party animal who loves dancing. Since he was diagnosed with Phelan-MCDermid syndrome at birth, he gets yearly brain MRIs - and one revealed a tumor when Hux turned 3. After a year of treatment, Hux has remained cancer-free!
